Seeing the wood from the trees

With all the breathless hype of late around the rise of ADCs and even some bispecifics, are the data likely to catapult these early stage agents into future stars?

Are there signals we can explore to try and answer this key question?

It’s easy to convince oneself something looks better than what went before – is this truly the case?

In this review we explore pros and cons around half a dozen early stage agents in clinical development and explain why some might go forward while others might experience future setbacks…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by